Production-ready in weeksTalk to a Quality Expert

Free tool · No login required

Pharma AI Literacy Center

Benchmark yourself across five domains against what the research and both regulators actually say. Eight modules, a 20-question assessment, and a reference glossary built for US and EU rulebooks at once.

20 questions · ~6 min8 modules · ~54 min71 glossary terms

~6 min · 20 questions · instant results

About this assessment

How AI-literate are you, really? McKinsey finds only 1% of leaders call their company's AI rollout mature, and employees use AI at roughly three times the rate their leaders think. If you work in pharma, you now answer to two rulebooks at once: FDA's risk-based credibility framework at home, and the EU's AI Act and GMP Annex 22 for anything touching the European market. This check benchmarks you across five domains against what the research and both regulators actually say. 20 questions, ~6 minutes, instant results, nothing stored.

Question 1 of 20Domain A

The fundamental difference between a machine-learning model and traditional software:

Educational content only — not legal or regulatory advice. Regulatory guidance cited here includes drafts (FDA AI credibility guidance; EU GMP Annex 22) as of August 2026; verify against final texts before relying on them in submissions. Company-reported figures (Merck CSR timings, Sanofi results) are labeled where used. MIT's ~95% pilot figure carries its own caveat (~150 interviews, contested definitions, not peer-reviewed). Re-check sources on module finalization.

Reference guide

Pharma AI literacy — assessment, modules, and glossary

Free training for regulated life sciences: benchmark your AI literacy across FDA and EU rulebooks, work through eight modules (~54 minutes), and search 71 glossary terms from AI Act Article 4 to GMP Annex 22.

Eight learning modules

Each module includes lesson content, an interactive exercise, and a knowledge check. Complete all eight to earn an Article 4 completion certificate.

  1. Module 1 · ~6 min

    The Machine That Learns (and Its Jagged Edge)

    Distinguish learned vs. programmed behavior, understand training and inference, and internalize the jagged frontier.

  2. Module 2 · ~6 min

    Generative AI: Fluent, Fast, and Sometimes Wrong

    Understand next-word prediction, recognize hallucination as structural, and know the documented consequences in regulated settings.

  3. Module 3 · ~7 min

    The Potential: What AI Makes Possible in Life Sciences

    Grasp the scale of the opportunity across the value chain, know the landmark proof points, and hold ambition and evidence in the same hand.

  4. Module 4 · ~7 min

    The State of Play: What Pharma Is Actually Doing

    Know the verified case studies, understand why most pilots fail, and learn what winners do differently.

  5. Module 5 · ~8 min

    The US Rulebook: FDA's Risk-Based World

    Command the four pillars of the US framework and know the 2026 policy landscape.

  6. Module 6 · ~8 min

    The EU & Global Rulebook: The Act, Annex 22, and Beyond

    Know what the EU AI Act and Annex 22 require, when they reach US companies, and where MHRA, EMA, and ICH fit.

  7. Module 7 · ~6 min

    Trust, Data, and Records

    Apply confidentiality and ALCOA+ discipline to AI work in both jurisdictions; understand shadow AI; see why trust drives value capture.

  8. Module 8 · ~6 min

    The AI-Fluent Professional: A Working Method

    Adopt the 4D framework, know the training threshold, and build the delegate-describe-discern-be-diligent habit.

Glossary — 71 pharma AI terms

Definitions aligned to FDA AI credibility guidance, EU AI Act, GMP Annex 11/22, and GxP data integrity — from agentic AI and ALCOA+ to validation and the jagged frontier.

Agent / agentic AI
AI that doesn't just answer questions but plans and executes multi-step tasks using tools: querying systems, drafting and filing documents, triggering workflows.
AI literacy
Defined in EU AI Act Article 3(56) as the "skills, knowledge and understanding" that allow providers, deployers, and affected persons "to make an informed deployment of AI systems, as well as to gain awareness about the opportunities and risks of AI and possible harm it can cause.
AI system (EU AI Act definition)
"A machine-based system that, for explicit or implicit objectives, infers, from the input it receives, how to generate outputs such as predictions, content, recommendations, or decisions" with some level of autonomy and possible post-deployment adaptiveness.
ALCOA+
The data-integrity mnemonic: records must be Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available.
AlphaFold
DeepMind's protein-structure prediction system, the subject of the 2024 Nobel Prize in Chemistry.
Annex 11 (EU GMP, draft revision)
The EU's rules for computerised systems in GMP, under revision in the same 2025 consultation as Annex 22.
Annex 22 (EU GMP, draft)
The first GMP-specific AI guideline, drafted by the EMA/PIC/S inspectors' working group (consultation July–October 2025; still draft).
Article 4 (EU AI Act)
The AI-literacy obligation: providers and deployers "shall take measures to ensure, to their best extent, a sufficient level of AI literacy of their staff and other persons dealing with the operation and use of AI systems on their behalf," proportionate to technical knowledge, experience, education, and context of use.
Bias (model bias)
Systematic error a model inherits from unrepresentative training data or flawed labels: an inspection model trained mostly on one vial format underperforming on another, a triage model that under-flags rare event types it seldom saw.
Black box
A model whose internal decision logic can't be directly inspected, true of most deep-learning systems, whose "reasoning" is distributed across millions of parameters.
Centaur / Cyborg
The two successful human-AI working styles identified in the Harvard/BCG "jagged frontier" experiment.
Confidence score
The model's own numeric estimate of how certain it is about a given output.
Context of use (COU)
FDA's pivotal term: "the specific role and scope of the AI model used to address a question of interest": what the model does, how its output will be used, and what other evidence sits alongside it.
Context window
The bounded amount of text an LLM can consider in one exchange.
Credibility assessment (FDA)
The seven-step process in FDA's January 2025 draft guidance for trusting an AI model in regulatory decision-making: (1) define the question of interest; (2) define the COU; (3) assess model risk (influence × consequence); (4) plan the credibility activities; (5) execute; (6) document results and deviations; (7) determine adequacy for the COU.
CSA (Computer Software Assurance)
FDA's modern philosophy of software validation: draft 2022, finalized September 24, 2025 (CDRH/CBER; updated February 2026), formally displacing the documentation-heavy CSV tradition for production and quality-system software.
CSV (Computer System Validation)
The traditional GxP discipline of documented evidence that a computerized system does what it's intended to do, historically implemented through IQ/OQ/PQ protocols and extensive scripted testing.
Data drift / model drift
The silent degradation mode of deployed AI: the real world shifts away from the training data (new product format, new camera, new supplier's raw material, new documentation style), and performance decays without any code change or error message.
Data governance
The organizational discipline covering how data is sourced, stored, accessed, retained, and used: consent, lineage, quality, security.
Dataset (training / validation / test)
The three-way split at the heart of honest ML evaluation: the *training set* teaches the model; the *validation set* (in the ML sense, tuning, not GxP validation) guides development choices; the *test set* is held back and touched only to measure final performance.
De novo design (generative chemistry)
Using generative models to propose entirely new molecules or proteins with desired properties, rather than screening libraries of existing compounds.
Decision consequence (FDA)
One of the two axes of FDA model risk: "the significance of an adverse outcome resulting from an incorrect decision.
Deep learning
Machine learning built on many-layered neural networks, responsible for the modern leaps in vision (Amgen's vial inspection) and language (every LLM).
Deterministic
Property of producing identical output for identical input, every time.
Digital twin
A continuously updated computational model of a physical asset or process, a bioreactor, a production line, even a patient population, used to simulate, predict, and optimize before touching the real thing.
Explainability (XAI)
Techniques that expose *why* a model produced an output: SHAP and LIME attribute a prediction to input features; heat maps show which image regions drove a vision model's call.
"Falling asleep at the wheel"
The over-reliance failure mode named in the jagged-frontier research: as AI output quality rises, human vigilance falls, and the errors that remain are precisely the ones no one is checking for.
Federated learning
Training a shared model across multiple organizations or sites without moving the underlying data: the model travels, the data stays put.
Fine-tuning
Additional training of a general-purpose model on domain-specific data (your deviation histories, your SOP corpus) to specialize its behavior.
Foundation model / GPAI
A very large model trained on broad data that many downstream applications build on.
4-eyes principle (Annex 22)
The draft's control for test-data independence: a person *without access to the training data* independently reviews test outcomes, so no single individual can (accidentally or otherwise) let training data contaminate the test.
GAMP 5 (2nd ed.) / GAMP AI Guide
ISPE's practitioner frameworks for computerized-system quality.
Generative AI
AI that produces new content, text, images, code, structures, rather than only classifying or predicting.
Grounding
Constraining a model's outputs to verifiable sources, documents retrieved at question time, structured data, citations a human can follow, rather than the model's parametric memory.
Guardrails
The layered constraints on AI behavior: system-level (what the deployment will refuse), application-level (input/output filters, allowed data sources), and prompt-level (your own instructions, "flag missing information rather than guessing").
Hallucination
The generation of confident, fluent, well-formatted content that is factually wrong or fabricated, invented citations, plausible-but-false numbers, nonexistent guidance documents.
High-risk AI (EU AI Act)
The Act's most regulated tier, defined by two routes: safety components of products under listed EU legislation (medical devices via MDR/IVDR, note medicinal-products law is *not* on that list), or uses listed in Annex III (biometrics, critical infrastructure, employment, essential services…).
Human-in-the-loop (HITL)
An oversight design where a human reviews or approves AI output before it takes effect.
In silico
Performed by computer simulation, the third member of the classic triad with in vitro (glassware) and in vivo (living organisms).
Inference
Running a trained model on new data to produce an output, the "use" phase, as distinct from training.
Input space
The range and character of data a model was designed and validated for, vial formats, lighting conditions, document types, populations.
Jagged frontier
The defining metaphor for AI capability, from the 758-consultant Harvard/BCG field experiment: the boundary of what AI does well is uneven and invisible, +12% task completion, +25% speed, +40% quality inside it; −19 percentage points accuracy just outside it.
Knowledge graph
A data structure representing entities (drugs, targets, adverse events, batches, suppliers) and the relationships between them, so machines can traverse connections the way an expert's intuition does.
Large language model (LLM)
A deep-learning model trained on vast text corpora to predict likely next tokens, from which capabilities in drafting, summarization, reasoning-like behavior, and code emerge.
Machine learning (ML)
Building models whose behavior is learned from data rather than explicitly programmed.
Model
The trained artifact itself: the architecture plus the learned parameters that map inputs to outputs.
Model influence (FDA)
The second axis of FDA model risk: "the contribution of the evidence derived from the AI model relative to other contributing evidence.
Model lifecycle
The full arc: data acquisition → training → evaluation → deployment → monitoring → retraining → retirement, with governance at each stage.
Multimodal AI
Models that work across data types at once: text, images, structured data, molecular structures, genomic sequences.
NIST AI Risk Management Framework (AI RMF)
The voluntary US framework (v1.
Overfitting
When a model memorizes its training data instead of learning generalizable patterns, spectacular on the training set, brittle in production.
Parameters
The numerical weights inside a model, millions to trillions of them, set during training and encoding everything it "knows.
Part 11 (21 CFR Part 11)
FDA's 1997 regulation on electronic records and electronic signatures: trustworthy records (validation, audit trails, protection, access control) and signatures that legally bind a person to content.
PCCP (Predetermined Change Control Plan)
FDA's mechanism (final guidance December 2024, device-side) letting a manufacturer pre-specify how an AI-enabled product will be modified, retraining triggers, performance bounds, update protocols, so in-bounds changes proceed without new marketing submissions.
Predictive maintenance
ML on equipment sensor data to forecast failures before they occur: vibration, temperature, cycle patterns.
Probabilistic
Producing outputs as likelihoods over possibilities rather than a single guaranteed answer, ML's native mode.
Prompt / prompt engineering
The instruction given to a generative model, and the craft of writing it well.
Question of interest (FDA)
Step one of the credibility framework: the specific question the AI model's evidence will help answer; e.
RAG (Retrieval-Augmented Generation)
Architecture in which the system first retrieves relevant passages from a controlled corpus (your SOPs, your regulations, your records) and requires the LLM to answer from them, typically with citations.
Real-world data / real-world evidence (RWD/RWE)
Health data gathered outside conventional trials (claims, EHRs, registries, wearables) and the evidence derived from it.
Self-driving lab
Closed-loop experimentation in which AI proposes the next experiment, robotic automation runs it, and the results retrain the model, iterating around the clock.
Shadow AI
Employees using personal, unsanctioned AI tools for work: pasting company content into consumer chatbots.
SHAP / LIME
The two feature-attribution techniques named in draft Annex 22.
Silicon ceiling
BCG's term (AI at Work 2025, n=10,600+) for the adoption gap between leadership and the front line: >75% of leaders and managers use genAI regularly versus 51% of frontline employees, with training access, not attitude, as the main differentiator.
Static model / locked model
A model whose parameters are frozen after training and validation; it changes only through controlled retraining and re-release.
Synthetic control arm
A comparison group for a clinical trial constructed from historical trial data and real-world data instead of newly randomized placebo patients.
10-20-70
BCG's empirical ratio for where AI-transformation effort must go: 10% algorithms, 20% technology and data infrastructure, 70% people, processes, and culture.
Test set (independent)
Data held back from all model development and used once, to measure honest performance.
Training / training data
Training is the optimization process that sets a model's parameters; training data is the example corpus it learns from.
Transparency
Operating openly about when AI is used, what it does, and its limits, toward employees, regulators, and affected persons.
Validation (of AI)
The umbrella activity: documented, risk-proportionate evidence that a model reliably does its job in its context of use.

Frequently asked questions

What is pharma AI literacy?

Pharma AI literacy is the skills and judgment to deploy, review, and govern AI in regulated life-sciences work — from understanding model limits and the jagged frontier to applying FDA credibility expectations and EU AI Act Article 4 obligations in GMP settings.

Who is the Pharma AI Literacy Center for?

Quality, manufacturing, validation, IT, data science, and leadership roles in pharma and biotech — anyone who needs to speak credibly about AI with regulators, auditors, or cross-functional teams in the US and EU.

How long does the assessment take?

The benchmark assessment has 20 multiple-choice questions across five domains and typically takes about six minutes. You receive instant scoring with domain breakdowns and module recommendations.

Does the tool cover FDA and EU requirements?

Yes. Five assessment domains and eight learning modules span AI fundamentals, pharma use cases, FDA's risk-based AI credibility framework, and EU AI Act / GMP Annex 22 expectations — with a 71-term glossary aligned to both rulebooks.

Is the Pharma AI Literacy Center free?

Yes. The assessment, all eight modules, glossary, score readout PDF, and Article 4 completion certificate are free with no login required.

Is this legal or regulatory advice?

No. Content is educational only. Draft guidance cited (FDA AI credibility; EU GMP Annex 22) should be verified against final texts before use in submissions or audits.